Trial NERELYFE Study
Cancer Type Breast Cancer
Hospital(s) Altnagelvin Hospital

Multicenter, multi-country, prospective, observational, post authorisation safety study to describe the incidence of discontinuation due to diarrhoea within the first 3 months of treatment with neratinib, in adult breast cancer patients treated in extended adjuvant in a real world setting: the NERLYFE study. Ancillary study: A Nerlyfe ancillary study to describe recurrence in breast cancer patients treated with neratinib in a real-world setting

Posted in .